Invivoscribe appoints Loui Madakamutil to lead its Therapeutics division as Chief Scientific Officer.admin2021-02-26T19:09:31+00:00September 8th, 2020|2020 Press Releases, Press Releases| Read More
Invivoscribe Launches New Division for Drug Development. Licenses Small Molecule Inhibitors from Domainex to Treat Acute Myeloid Leukemiaadmin2021-02-26T19:09:41+00:00July 14th, 2020|2020 Press Releases, Press Releases| Read More
Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United Statesadmin2021-02-26T19:09:52+00:00May 19th, 2020|2020 Press Releases, Press Releases| Read More
Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.admin2021-02-26T19:10:05+00:00May 12th, 2020|2020 Press Releases, Press Releases| Read More
